Last Updated: 02 Jul 2025
Source: Statifacts
「すべてのCookieを受け入れる」をクリックすると、サイトのナビゲーション向上、サイト利用状況の分析、 およびマーケティング活動の支援のために、お使いのデバイスにCookieを保存することに同意したものとみなされます。
プライバシーポリシー
????????????2024??99?8,000??????????2034?????515?3,000?????????2025???2034????????????CAGR?17.84?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

| ???? | ?? |
| 2025?????? | 114?9000???? |
| 2034???????? | 515?3000???? |
| 2025???2034????????? | 17.84%?CAGR |
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????HSCT?????????????????3D?????????????????????????????????????????????????????????????????????????????????
???????AI????????????????????????????????AI??????????????????????????????????????????????????????AI??????????????????????????????????????????????????????????????????? ????AI????????????????????????????????AI???????????????????????????????????????????????
??????????????????????????????????????????????????????????????????CRISPR-Cas9??????????CAR T??????????????TIL?????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????T?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????CRISPR-Cas9???????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????? RHEACELL ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????CAR-T???????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
??
??????????????????????????????????FDA????????????????????????????????????????????????????????????
???????Vertex Pharmaceuticals??????????????????????????????????????????12???????10???????????????????10??????????????????????????????????????????
??
?????????????????????CMO???????????????????????????????????????????????????????????????
????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????CAR-T?????????????????????2026???????????????
????????????????????????????????? ??????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????3???????????????
??????????? ??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ???????????????????????????????????????????2seventy??????????????
??????????? ?????2024??????48,300,000???????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????????????FDA????????????
???????2024???????51,722,000???????????
?????????????????????????HIV?B??C?????????????????????????????????????1????????2000????10?????????????????1???HIV???????????????????
????????????2024????????28,754,000??????
発行元 Rohan Patil
Last Updated: 02 Jul 2025
Source: Statifacts
Last Updated: 02 Jul 2025
Source: Statifacts
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stem Cell Therapy | 5,704.60 | 6,587.80 | 7,647.30 | 8,931.00 | 10,501.90 | 12,422.90 | 14,757.60 | 17,605.10 | 21,108.00 | 25,371.30 | 30,431.50 |
| Immune Cell Therapy | 3,260.90 | 3,742.60 | 4,317.70 | 5,011.50 | 5,856.70 | 6,885.30 | 8,128.90 | 9,637.60 | 11,483.90 | 13,718.30 | 16,352.90 |
| Others (Tissue Engineering Cells, Somatic Cells) | 1,018.20 | 1,160.40 | 1,329.20 | 1,531.80 | 1,777.10 | 2,073.90 | 2,430.40 | 2,859.90 | 3,382.00 | 4,009.10 | 4,742.00 |
Last Updated: 02 Jul 2025
Source: Statifacts
| サブセグメント | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stem Cell Therapy | 5,704.60 | 6,587.80 | 7,647.30 | 8931 | 10,501.90 | 12,422.90 | 14,757.60 | 17,605.10 | 21108 | 25,371.30 | 30,431.50 |
| Immune Cell Therapy | 3,260.90 | 3,742.60 | 4,317.70 | 5,011.50 | 5,856.70 | 6,885.30 | 8,128.90 | 9,637.60 | 11,483.90 | 13,718.30 | 16,352.90 |
| Others (Tissue Engineering Cells, Somatic Cells) | 1,018.20 | 1,160.40 | 1,329.20 | 1,531.80 | 1,777.10 | 2,073.90 | 2,430.40 | 2,859.90 | 3382 | 4,009.10 | 4742 |
Cell therapy involves administering live cells into a patient to repair or replace damaged tissues, fight diseases, or restore normal function. It is commonly used in regenerative medicine and cancer treatment.
The main types include autologous (using the patient�s own cells) and allogeneic (using donor cells). CAR-T cell therapy and stem cell therapy are the most prominent applications.
The market is expanding due to rising chronic disease prevalence, technological advancements in cell processing, increased investment in regenerative medicine, and a growing number of FDA-approved cell therapies.
Major challenges include high development and manufacturing costs, complex logistics, scalability issues, and regulatory hurdles related to safety, quality, and long-term efficacy.
Key players include Novartis, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, Bluebird Bio, and Fate Therapeutics, among others actively developing therapies for cancer and rare diseases.
To get full access to our Market Insights, you need a Professional Account or a Business Suite.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.